← Leaderboards
Beth Diane Kirkpatrick
University Of Vermont & St Agric College
$19,353,029
Attributed
$22,281,008
Total exposure
18
Grants
17
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $6.9M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$42,616,571 · 19
By mechanism
P20$29,735,166 · 9
U01$10,725,803 · 2
M01$1,270,248 · 6
K08$651,375 · 1
R34$233,979 · 1
Top collaborators
- Sean A Diehl7 shared
- Jason W. Botten5 shared
- Anna Palmer Durbin2 shared
- Christopher D Huston1 shared
Most similar at University Of Vermont & St Agric College
Same institution · by research overlap
- Sean A Diehl$2,286,293
- Elizabeth Ross Colgate$280,629
- Christopher D Huston$6,704,821
Others in their field
Top investigators on “Research Personnel”
- David Heimbrook · Leidos Biomedical Research, Inc.$701,463,488
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Leonard Freedman · Leidos Biomedical Research, Inc.$557,978,666
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David R. Weir · University Of Michigan At Ann Arbor$364,053,504
- Judith S. Currier · University Of California Los Angeles$284,675,012
Research focus
Research PersonnelCommunicable DiseasesFundingInfectionVaccinesPreventUnited States National Institutes Of HealthPredictive ModelingInstitutionUniversitiesMentorsCenters Of Research ExcellenceLeadResponseVermontProgramsDesignInnovationFacultyGrantCore FacilityGrowthSafetyInfectious Diseases Research
Grant awards (51)
Translational Global Infectious Diseases Research Center$2,294,927
P20 · FY2025 · GM · contact PI
Administrative Core$1,057,442
P20 · FY2025 · GM · contact PI
Mechanisms of Protection and Durability for a Live Attenuated Tetravalent Dengue Vaccine$670,995
U01 · FY2025 · AI
Translational Global Infectious Disease Reseach Center$306,995
P20 · FY2025 · GM · contact PI
Translational Global Infectious Diseases Research Center$2,288,116
P20 · FY2024 · GM · contact PI
A Phase II Evaluation of the Safety and Protective Efficacy of the Live Attenuated Tetravalent Dengue Vaccine TetraVax-DV with Challenge by the Recombinant DENV-2 Virus in a Dengue Endemic Population$1,224,706
U01 · FY2024 · AI · contact PI
Administrative Core$1,029,853
P20 · FY2024 · GM · contact PI
Translational Research to Prevent and Control Global Infectious Diseases(Translational Global Infectious Diseases Research Center, TGIR)$956,407
P20 · FY2024 · GM · contact PI
Mechanisms of Protection and Durability for a Live Attenuated Tetravalent Dengue Vaccine$635,890
U01 · FY2024 · AI
Translational Global Infectious Diseases Research Center$2,287,497
P20 · FY2023 · GM · contact PI
A Phase II Evaluation of the Safety and Protective Efficacy of the Live Attenuated Tetravalent Dengue Vaccine TetraVax-DV with Challenge by the Recombinant DENV-2 Virus in a Dengue Endemic Population$1,249,406
U01 · FY2023 · AI · contact PI
Administrative Core$962,333
P20 · FY2023 · GM · contact PI
Translational Research to Prevent and Control Global Infectious Diseases (Translational Global Infectious Diseases Research Center, TGIR).$962,333
P20 · FY2023 · GM · contact PI
Administrative Core$877,523
P20 · FY2023 · GM · contact PI
Mechanisms of Protection and Durability for a Live Attenuated Tetravalent Dengue Vaccine$608,440
U01 · FY2023 · AI
Translational Research to Prevent and Control Global Infectious Diseases (Translational Global Infectious Diseases Research Center, TGIR).$2,204,090
P20 · FY2022 · GM · contact PI
A Phase II Evaluation of the Safety and Protective Efficacy of the Live Attenuated Tetravalent Dengue Vaccine TetraVax-DV with Challenge by the Recombinant DENV-2 Virus in a Dengue Endemic Population$1,239,797
U01 · FY2022 · AI · contact PI
Administrative Core$952,419
P20 · FY2022 · GM · contact PI
Mechanisms of Protection and Durability for a Live Attenuated Tetravalent Dengue Vaccine$608,997
U01 · FY2022 · AI
Translational Research to Prevent and Control Global Infectious Diseases (Translational Global Infectious Diseases Research Center, TGIR).$1,658,162
P20 · FY2021 · GM · contact PI
Administrative Core$710,899
P20 · FY2021 · GM · contact PI
Mechanisms of Protection and Durability for a Live Attenuated Tetravalent Dengue Vaccine$611,648
U01 · FY2021 · AI
Multi-Scale Modeling of SARS-CoV-2 Dissemination Dynamics$322,445
P20 · FY2021 · GM · contact PI
Translational Research to Prevent and Control Global Infectious Diseases (Translational Global Infectious Diseases Research Center, TGIR).$2,206,711
P20 · FY2020 · GM · contact PI
A Phase II Evaluation of the Safety and Protective Efficacy of the Live Attenuated Tetravalent Dengue Vaccine TetraVax-DV with Challenge by the Recombinant DENV-2 Virus in a Dengue Endemic Population$1,319,208
U01 · FY2020 · AI · contact PI
Administrative Core$857,478
P20 · FY2020 · GM · contact PI
Mechanisms of Protection and Durability for a Live Attenuated Tetravalent Dengue Vaccine$615,445
U01 · FY2020 · AI
Translational Research to Prevent and Control Global Infectious Diseases (Translational Global Infectious Diseases Research Center, TGIR).$2,244,419
P20 · FY2019 · GM · contact PI
A Phase II Evaluation of the Safety and Protective Efficacy of the Live Attenuated Tetravalent Dengue Vaccine TetraVax-DV with Challenge by the Recombinant DENV-2 Virus in a Dengue Endemic Population$1,300,717
U01 · FY2019 · AI · contact PI
Administrative Core$832,856
P20 · FY2019 · GM · contact PI
Mechanisms of Protection and Durability for a Live Attenuated Tetravalent Dengue Vaccine$640,554
U01 · FY2019 · AI
Translational Research to Prevent and Control Global Infectious Diseases (Translational Global Infectious Diseases Research Center, TGIR).$2,603,461
P20 · FY2018 · GM · contact PI
Administrative Core$882,971
P20 · FY2018 · GM · contact PI
A Phase I/II Trial of the Safety, Tolerability and Immunogenicity of a Live Attenuated Tetravalent Dengue Virus Vaccine in Adults in Dengue-Endemic Bangladesh$233,979
R34 · FY2016 · AI · contact PI
VERMONT COBRE: PROJECT 2: INNATE IMMUNE RESPONSES TO CRYPTOSPORIDIUM PARVUM$177,049
P20 · FY2011 · RR · contact PI
CLINICAL TRIAL: PHASE I EVALUATION OF A LIVE ATTENUATED DEN4 VACCINE$492,094
M01 · FY2010 · RR · contact PI
VERMONT COBRE: PROJECT 2: INNATE IMMUNE RESPONSES TO CRYPTOSPORIDIUM PARVUM$168,613
P20 · FY2010 · RR · contact PI
CAMPYLOBACTER JEJUNI CHALLENGE: ASSESSMENT OF HOMOLOGOUS PROTECTION$53,916
M01 · FY2010 · RR · contact PI
CAMPYLOBACTOR JEJUNI CHALLENGE MODEL DEVELOPMENT: DOSE-RANGING STUDY$1,712
M01 · FY2010 · RR · contact PI
CAMPYLOBACTOR JEJUNI CHALLENGE MODEL DEVELOPMENT: DOSE-RANGING STUDY$274,169
M01 · FY2009 · RR · contact PI
VERMONT COBRE: PROJECT 2: INNATE IMMUNE RESPONSES TO CRYPTOSPORIDIUM PARVUM$167,746
P20 · FY2009 · RR · contact PI
CAMPYLOBACTOR JEJUNI CHALLENGE MODEL DEVELOPMENT: DOSE-RANGING STUDY$434,620
M01 · FY2008 · RR · contact PI
VERMONT COBRE: PROJECT 2: INNATE IMMUNE RESPONSES TO CRYPTOSPORIDIUM PARVUM$173,872
P20 · FY2008 · RR · contact PI
Gamma-Delta T cells and Cryptosporidiosis$134,595
K08 · FY2008 · AI · contact PI
VERMONT COBRE: PROJECT 2: INNATE IMMUNE RESPONSES TO CRYPTOSPORIDIUM PARVUM$209,902
P20 · FY2007 · RR · contact PI
Gamma-Delta T cells and Cryptosporidiosis$134,595
K08 · FY2007 · AI · contact PI
CAMPYLOBACTOR JEJUNI CHALLENGE MODEL DEVELOPMENT: DOSE-RANGING STUDY$13,737
M01 · FY2007 · RR · contact PI
VERMONT COBRE: PROJECT 2: INNATE IMMUNE RESPONSES TO CRYPTOSPORIDIUM PARVUM$338,647
P20 · FY2006 · RR · contact PI
Gamma-Delta T cells and Cryptosporidiosis$134,595
K08 · FY2006 · AI · contact PI
Gamma-Delta T cells and Cryptosporidiosis$123,795
K08 · FY2005 · AI
Gamma-Delta T cells and Cryptosporidiosis$123,795
K08 · FY2004 · AI